Daxor Announces Valley Hospital of Ridgewood, NJ Purchases Blood Volume Analyzer BVA-100

NEW YORK, NY--(Marketwire - June 15, 2007) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed purchase order for the Blood Volume Analyzer BVA-100 from The Valley Hospital of Ridgewood, New Jersey.

The Valley Hospital is a fully accredited, acute care, not-for-profit, 451-bed licensed hospital serving more than 440,000 people in 32 towns and the adjoining communities in Bergen County, New Jersey. Valley Hospital has earned the Gold Seal of Approval from the Joint Commission on Accreditation of Healthcare Organizations and is known throughout northern New Jersey for its medical and technical excellence. The Valley Hospital is the second busiest hospital in the state of New Jersey, based on admissions data, with more than one-third of annual admission occurring for same-day services through its Same-Day Services Program, and more than half of all surgeries performed on a same-day basis. The Valley Hospital is also a leader in the field of cardiology services through its Valley Columbia Heart Center, and is certified by the American College of Surgeons for its Community Hospital Comprehensive Cancer Program.

Daxor's Blood Volume Analyzer BVA-100 will be located within The Valley Hospital's Nuclear Medicine Department. The BVA-100 will be utilized to diagnose and treat blood volume abnormalities that often occur in patients with hypertension, heart failure, syncope, anemia, and for pre- and post-surgical testing.

Other nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer are The Mayo Clinic, The Cleveland Clinic, and New York University Medical Center. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 or Diane Meegan Investor Relations 212-330-8512 .